R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
In 243 antiretroviral-naive human immunodeficiency-infected patients starting a first-line-protease inhibitor (mainly nelfinavir)-containing therapy, the presence of the polymorphism R57K in the protease at the inception of therapy was independently associated with a higher rate of virological failure.
Laboratoire de Virologie, Hôpital Pellegrin, Bordeaux, France. bernard.masquelier@chu-bordeaux.fr
Bernard
B
Masquelier
Cecile
C
Droz
Martin
M
Dary
Christian
C
Perronne
Virginie
V
Ferré
Bruno
B
Spire
Diane
D
Descamps
François
F
Raffi
Françoise
F
Brun-Vézinet
Geneviève
G
Chêne
D000328:Adult; D015331:Cohort Studies; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019888:Nelfinavir / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000096:biosynthesis / Q000235:genetics; D017211:Treatment Failure
D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D016333:HIV Protease; D019888:Nelfinavir